Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zanamivir

S L Waghorn1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|May 20, 1998
PubMed
Summary
This summary is machine-generated.

Zanamivir, a neuraminidase inhibitor, effectively combats influenza A and B. Clinical trials show it prevents infection and alleviates symptoms without resistance development in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Zanamivir represents a novel class of selective influenza virus neuraminidase inhibitors.
  • It demonstrates in vitro inhibition of both influenza A and B virus replication.

Purpose of the Study:

  • To evaluate the efficacy of zanamivir in preventing and treating influenza.
  • To assess the development of viral resistance to zanamivir.

Main Methods:

  • In vitro studies assessing viral replication inhibition.
  • Ferret model studies for viral replication and pyrexia.
  • Clinical trials involving inhaled and intranasal zanamivir administration.
  • Human experimental intranasal infection models.

Related Experiment Videos

Main Results:

  • Zanamivir reduced viral replication and fever in the ferret model.
  • No evidence of zanamivir resistance emerged in clinical isolates.
  • Intranasal zanamivir prevented influenza infection in humans.
  • Combined inhaled and intranasal zanamivir prevented influenza outbreaks in a nursing home.
  • Inhaled zanamivir shortened symptom duration in confirmed influenza cases.

Conclusions:

  • Zanamivir is effective in preventing and treating influenza.
  • The drug shows a low propensity for resistance development in clinical settings.
  • Zanamivir offers a viable therapeutic option for influenza management.